Accumulating Clinical Experience and Data on hADM

GC Green Cross Wellbeing is establishing an advisory committee of medical professionals to strengthen the clinical evidence for its human acellular dermal matrix (hADM) product, Giselle Rebonne.


On July 29, GC Green Cross Wellbeing announced that it has launched the Giselle Rebonne Advisory Committee, consisting of six experts in the field of aesthetics, and plans to expand its academic activities.


The advisory committee includes Dr. Gongchan Na, Director of Doctor Robin Clinic; Dr. Arim Min, Director of Min & Min Clinic; Dr. Giwook Kim, Director of Wirye ID Clinic; Dr. Kyunghoon Yoo, Director of Lumi Clinic; Dr. Kanghoon Choi, Director of Songdo Obliv Clinic; and Dr. Jisoo Guk, Director of It's Me Clinic Ansan Branch.


GC Green Cross Wellbeing announced on the 29th that it has launched the Giselle Rebonne Advisory Committee, consisting of six medical professionals in the aesthetic field, and will expand academic activities. GC Green Cross Wellbeing

GC Green Cross Wellbeing announced on the 29th that it has launched the Giselle Rebonne Advisory Committee, consisting of six medical professionals in the aesthetic field, and will expand academic activities. GC Green Cross Wellbeing

View original image

The committee will share real-world procedure experiences and clinical data on Giselle Rebonne, and discuss procedural methods to enhance both safety and efficacy. Additionally, the committee is developing academic materials to introduce domestic medical professionals' procedural experiences internationally and is jointly planning global academic activities.


GC Green Cross Wellbeing plans not only to promote Giselle Rebonne, but also to develop and disseminate "combination procedure protocols" involving its recently launched lineup. The company aims to incorporate expert feedback from the early stages of product development and to introduce differentiated ECM (extracellular matrix)-based products for use in actual clinical practice.



A company representative stated, "We will continue to collaborate closely with medical professionals to consistently secure clinical evidence and to further expand academic activities based on safety and efficacy."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing